Methods and compositions are provided herein for non-invasive administration of an adenoviral vector (Ad-vector) vaccine with an adjuvant, such as a TLR3 agonist. These methods provide, for example, an increase in the immune response to the vaccine, an increase in the immunogenicity of the Ad-vector vaccine, an antigen sparing effect and improved safety with an effective protective immune response to the vaccine.